The relationship between serum CX3CL1 level and cognitive dysfunction in patients with white matter hyperintensity

doi:10.3969/j.issn.1006-7795.2023.01.002

Abstract

Abstract: Objective To explore the correlation between serum chemokine C-X3-C-motif ligand 1 (CX3CL1), also know as fractalkine (Fkn). levels and cognitive dysfunction in patients with white matter hyperintensity (WMH). Methods A total of 152 patients with cerebral small vessel disease (CSVD) enrolled in the First Affiliated Hospital of Xinxiang Medical University from March 2020 to August 2022 were collected. The general clinical data of patients, the routine sequence of cranial magnetic resonance imaging (MRI), biochemical indicators, serum CX3CL1 level, and Mini-mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) cognitive scores were collected, and the correlation between serum CX3CL1 levels and white matter hyperintensity and cognitive function was analyzed. Results A total of 152 participants were enrolled and divided into the group with normal cognitive function and the group of cognitive dysfunction according to the MMSE results, with the mean age of (59.60±8.84) years and (62.91±7.99)years, respectively. The correlation analysis results showed that CX3CL1 level and apparent space were negatively correlated with executive function, attention, and orientation.Regression analysis showed that CX3CL1 levels and white matter high-signal were risk factors for cognitive dysfunction. Receiver operating characteristic (ROC) curve analysis suggested that CX3CL1 levels may have potential predictive value for cognitive impairment. Conclusion Serum CX3CL1 levels and white matter hyperintensity are associated with cognitive function, and elevated serum CX3CL1 levels are risk factors for the development of cognitive dysfunction.

Key words: chemokine C-X3-C-motif ligand 1 (CX3CL1), white matter hyperintensity (WMH), cognitive function, cerebral small vessel disease (CSVD)

CLC Number:

R742

Li Qiong, Zhao Jianhua, Liu Hao, Wang Fan, Li Qing, Chen Xiyan, Cai Ruiyan, Wu Qingwu, Zhang Jian, Ji Sibei, Lu Chengbiao, Li Shaomin. The relationship between serum CX3CL1 level and cognitive dysfunction in patients with white matter hyperintensity[J]. Journal of Capital Medical University, 2023, 44(1): 6-12.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.01.002

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I1/6

References

[1] De Havenon A, Sheth K N, Yeatts S D, et al. White matter hyperintensity progression is associated with incident probable dementia or mild cognitive impairment[J]. Stroke Vasc Neurol, 2022, 7(4): 364-366.
[2] Pawelec P, Ziemka-Nalecz M, Sypecka J, et al. The impact of the CX3CL1/CX3CR1 axis in neurological disorders[J]. Cells, 2020, 9(10): 2277.
[3] Harrison J K, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia[J]. Proc Natl Acad Sci U S A, 1998, 95(18): 10896-10901.
[4] Lauro C, Chece G, Monaco L, et al. Fractalkine modulates microglia metabolism in brain ischemia[J]. Front Cell Neurosci, 2019, 13: 414.
[5] Liu Y, Zhang T X, Meng D W, et al. Involvement of CX3CL1/CX3CR1 in depression and cognitive impairment induced by chronic unpredictable stress and relevant underlying mechanism[J]. Behav Brain Res, 2020, 381: 112371.
[6] Liu Y, Wu X M, Luo Q Q, et al. CX3CL1/CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK/PKC pathway[J]. J Cereb Blood Flow Metab, 2015, 35(10): 1623-1631.
[7] Sheridan G K, Murphy K J. Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage[J]. Open Biol, 2013, 3(12): 130181.
[8] Bolós M, Llorens-Martín M, Perea J R, et al. Absence of CX3CR1 impairs the internalization of Tau by microglia[J]. Mol Neurodegener, 2017, 12(1): 59.
[9] Sunnemark D, Eltayeb S, Nilsson M, et al. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin[J]. J Neuroinflammation, 2005, 2: 17.
[10] Rogers J T, Morganti J M, Bachstetter A D, et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity[J]. J Neurosci, 2011, 31(45): 16241-16250.
[11] Suresh P, Phasuk S, Liu I Y. Modulation of microglia activation and Alzheimer's disease: CX3 chemokine ligand 1/CX3CR and P2X7R signaling[J]. Tzu Chi Med J, 2021, 33(1): 1-6.
[12] Li A, Zhao J Y, Fan C Z, et al. Delivery of exogenous proteins by mesenchymal stem cells attenuates early memory deficits in a murine model of Alzheimer's disease[J]. Neurobiol Aging, 2020, 86: 81-91.
[13] S′lusarczyk J, Trojan E, Wydra K, et al. Beneficial impact of intracerebroventricular fractalkine administration on behavioral and biochemical changes induced by prenatal stress in adult rats: possible role of NLRP3 inflammasome pathway[J]. Biochem Pharmacol, 2016, 113: 45-56.
[14] Zheng L, Wang Y, Shao B, et al. Multiple mild stimulations reduce membrane distribution of CX3CR1 promoted by annexin a1 in microglia to attenuate excessive dendritic spine pruning and cognitive deficits caused by a transient ischemic attack in mice[J]. Neurosci Bull, 2022, 38(7): 753-768.
[15] Lyons A, Lynch A M, Downer E J, et al. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attentuates microglial activation in vivo and in vitro[J]. J Neurochem, 2009, 110(5): 1547-1556.
[16] Scianni M, Antonilli L, Chece G, et al. Fractalkine (CX3CL1) enhances hippocampal N-methyl-D-aspartate receptor (NMDAR) function via D-serine and adenosine receptor type A2 (A2AR) activity[J]. J Neuroinflammation, 2013, 10: 108.
[17] 于鸿益, 贾仲仪, 张忠玲. 小胶质细胞参与脑白质高信号病理生理学的机制[J]. 国际脑血管病杂志, 2021, 29(6): 467-470.
[18] Meng L F, Zhao J H, Liu J L, et al. Cerebral small vessel disease and cognitive impairment[J]. J Neurorestoratology, 2019, 7(4): 184-195.
[19] Zhang Q X, He L, Chen M, et al. PSD-93 mediates the crosstalk between neuron and microglia and facilitates acute ischemic stroke injury by binding to CX3CL1[J]. J Neurochem, 2021, 157(6): 2145-2157.
[20] Bemiller S M, Maphis N M, Formica S V, et al. Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy[J]. J Neuroinflammation, 2018, 15(1): 278.
[21] Winter A N, Subbarayan M S, Grimmig B, et al. Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice[J]. J Neuroinflammation, 2020, 17(1): 157.
[22] Takei Y, Amagase Y, Iida K, et al. Alteration in peritoneal cells with the chemokine CX3CL1 reverses age-associated impairment of recognition memory[J]. Geroscience, 2022, 44(4): 2305-2318.
[23] Bollinger J L, Wohleb E S. The formative role of microglia in stress-induced synaptic deficits and associated behavioral consequences[J]. Neurosci Lett, 2019, 711: 134369.
[24] Bollinger J L, Collins K E, Patel R, et al. Behavioral stress alters corticolimbic microglia in a sex-and brain region-specific manner[J]. PLoS One, 2017, 12(12): e0187631.
[25] Spiteri A G, Wishart C L, Pamphlett R, et al. Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function[J]. Acta Neuropathol, 2022, 143(2): 179-224.
[26] Nash K R, Lee D C, Hunt J B, Jr, et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy[J]. Neurobiol Aging, 2013, 34(6): 1540-1548.